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Abstract
Objectives Rheumatoid arthritis (RA) patients show an earlier circadian rhythm (i.e. serum melatonin peaks earlier during the
night, indicating an earlier timing of the internal circadian pacemaker). In the current study, we examined whether the
chronotype, which is influenced by the circadian rhythm, is also earlier. In addition, we explored whether chronotype is related
to disease activity and patient-reported outcomes.
Methods The chronotype (Munich Chronotype Questionnaire) of patients with RA (n = 121; mean age 60 years, 73% female)
was compared with that of subjects from the general population (norm group; n = 1695) with a one-sample t test. In addition, we
investigated chronotype in relation to disease activity (Disease Activity Score; DAS), reported morning stiffness, fatigue
(Checklist Individual Strength), and health-related quality of life (RAND-36).
Results The chronotype of patients with RA was, on average, 23 min (95% CI, 15 to 31 min) earlier than that of the norm group
(t(115) = − 5.901, p < 0.001, d = 0.55). Chronotype was not related to disease activity or patient-reported outcomes (p > 0.05).
Conclusion As expected, chronotype was earlier in RA patients. However, in this correlational study, chronotype was not related
to disease activity or patient-reported outcomes. An experimental study is needed to examine whether delaying the circadian
rhythm has a positive influence on these outcomes. This insight could improve our understanding of the pathophysiology of RA
and contribute to exploring new treatment possibilities.
Keywords Chronobiology . Chronotype . Disease activity . Patient-reported outcomes . Rheumatoid arthritis
* G. Esther A. Habers
g.e.a.habers@fsw.leidenuniv.nl
1 Health, Medical, and Neuropsychology Unit, Institute of Psychology,
Leiden University, Wassenaarseweg 52, 2333 Leiden, AK, the
Netherlands
2 Leiden Institute for Brain and Cognition, Leiden, the Netherlands
3 Department of Rheumatology, Leiden University Medical Center,
Leiden, the Netherlands
4 Department of Cell and Chemical Biology/Department of
Dermatology, Leiden University Medical Center, Leiden, the
Netherlands
5 Department of Psychosocial Research and Epidemiology,
Netherlands Cancer Institute, Amsterdam, the Netherlands
6 Department of Psychiatry, Leiden University Medical Center,
Leiden, the Netherlands
7 Industrial Design Engineering, Delft University of Technology,
Delft, the Netherlands
8 Erasmus School of Health Policy and Management, Erasmus
University, Rotterdam, the Netherlands
Key Points
• This is the first study examining chronotype in patients with rheumatoid arthritis, and how chronotype relates to disease activity and patient-reported
outcomes.
• We found an earlier chronotype in patients with rheumatoid arthritis than in subjects from the general population.
• In this correlational study, chronotype was not related to disease activity or patient-reported outcomes. An experimental study is needed to examine




Chronobiological research in relation to rheumatoid arthritis
(RA) goes back several decades [1] and continues to be per-
formed to improve our understanding of the pathophysiology
of RA. It has been noted, for instance, that shift work is asso-
ciated with an increased risk for developing RA [2].
Furthermore, daily fluctuations have been observed in pa-
tients’ symptoms (e.g. pain and stiffness), with most pain
and stiffness experienced in the early morning. The underly-
ing cause of this morning peak in symptom severity seems to
be the increase of pro-inflammatory cytokines during the
night. One finding that supports this idea is that administration
of glucocorticoids during the night is indeed more effective
than morning treatment [3].
Circadian rhythms are endogenous rhythms that follow ap-
proximately a 24-h cycle. The rhythms are entrained to the
environment by zeitgebers, such as the light-dark cycle. Well-
functioning circadian rhythms are essential for the healthy
functioning of all bodily systems. An important signalling
hormone of the circadian rhythm is melatonin. It is directed
by the suprachiasmatic nucleus, which is the internal central
circadian pacemaker.
Circadian rhythm alterations are thought to play an impor-
tant role in the pathophysiology of RA [3]. It has been shown
that in patients with RA serum melatonin peaks earlier in the
night [4], indicating an earlier timing of the circadian rhythm.
Furthermore, circadian rhythms of some immune cell popula-
tions were found to be absent, new [5], or enhanced [6] in
patients with active RA, compared to those in healthy
subjects.
Circadian rhythms are one of the factors that influence
an individual’s chronotype. Each individual’s chronotype
reflects the phase of entrainment, which is the relation be-
tween the internal day and external day. The chronotype
can be calculated from sleep times: often the half-way
point between sleep onset and sleep end (i.e. mid-sleep)
is used as a measure of a subject’s chronotype. It has not
yet been explored whether the chronotype is different in
patients with RA than in subjects from the general popula-
tion. Insight into the chronotype and its relation with dis-
ease activity and patient-reported outcomes can contribute
to our understanding of the pathophysiology of RA. This
provides a possible starting point for exploring new treat-
ment possibilities.
Therefore, in the current study, the first aim was to examine
whether the chronotype was earlier in patients with RA than in
subjects from the general population. Given the strong relation
between the timing of melatonin onset and mid-sleep in the
general population [7], and given that melatonin peaks were
earlier in patients with RA [4], we expected to find an earlier
chronotype in patients with RA than in subjects from the gen-
eral population.
Secondly, we explored whether chronotype was related to
disease activity and to patient-reported outcomes (i.e. reported
morning stiffness, fatigue, and health-related quality of life
(HR-QoL)). Thirdly, for explorative reasons, we also assessed
the presence in the RA population of self-assessed sleep dis-
orders, including circadian rhythm sleep disorders.
Materials and methods
Study design and subjects
The study had a cross-sectional correlational design. The
population-based prospective Leiden Early Arthritis Clinic
(EAC), set up in 1993 [8], includes patients with confirmed
arthritis (after physical examination) and a symptom duration
of less than 2 years at the moment of inclusion in the EAC.
The inclusion and exclusion criteria for this cohort have been
published previously [8]. For this sub-study, additional exclu-
sion criteria included being unable to give informed consent
and/or lacking sufficient understanding of Dutch. Patients re-
ceived an email or, if no email address was available, a postal
letter with information about the current study and an in-
formed consent page/form. The Medical Ethical Committee
of the Leiden University Medical Center waived ethical ap-
proval; the study was carried out in compliance with the
Helsinki Declaration. Data were collected in the period 8–24
October 2015 (daylight saving time).
Measurements
Questionnaires for primary data collection
The questionnaires filled in by the subjects included the
Munich Chronotype Questionnaire, the Checklist Individual
Strength-20, RAND-36, and the Holland Sleep Disorders
Questionnaire. We also asked questions about the educational
level, marital status, and medication use.
Munich Chronotype Questionnaire (MCTQ) (study aims 1 and
2) Chronotype was calculated from the MCTQ, which as-
sesses the time of sleep onset and sleep end on work days
and free days over the preceding 2 weeks. A half-way point
between sleep onset and sleep end (i.e. mid-sleep) was calcu-
lated for both work and free days, reflecting the subject’s
chronotype. For the purposes of this study, the chronotype
(MSFsc) was expressed as mid-sleep on free days, with cor-
rection for sleep deficit accumulated during work days (see
reference [9] for detailed calculation).
Checklist Individual Strength (CIS)-20 (study aim 2) Fatigue
was assessed with the CIS-20 [10]. From this self-assessment
questionnaire, we determined the total score (20 items), and
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the subscale score subjective fatigue (8 items). Higher scores
reflect higher levels of fatigue.
RAND-36 (study aim 2) Health-related quality of life (HR-
QoL) was assessed with this self-assessment questionnaire
(36 items). Nine subscale scores were determined.
Transformed values ranged from 0 to 100, with higher values
corresponding to better health-related quality of life.
Holland Sleep Disorder Questionnaire (HSDQ) (study aim 3)
This self-assessment questionnaire was used to explore the
presence of sleep disorders based on the International
Classification of Sleep Disorders-2 [11]. Six categories of
sleep disorders are distinguished: circadian rhythm sleep dis-
orders, insomnia, parasomnia, hypersomnia, sleep-related
breathing disorders, and sleep-related movement disorders
[12].
Norm group data for timing sleep-wake behaviour in general
population (study aim 1)
Norm group data on chronotype were obtained from a
large Dutch general population database, for which the
MCTQ was completed online from 2003 to 2015; for
more details, see the reference article [13]. Individuals
from the general population (age range: 18–80 years)
who filled in this questionnaire in the period between
September 24 and October 24 (daylight saving time) were
selected for the current study to reflect a similar data
collection period as the RA patient sample. From this
norm group, the average values of MSFsc were available
for females and males separately, per 2 years, from 18 to
60 years (i.e. averages from 18 to 20 years, 20–22 years,
etc.), 60 to 65 years, and 65 to 80 years.
Since chronotype is dependent on age and gender, we
calculated age- and gender-re la ted norm values
(MSFsc,norm) by constructing a best fit line (polynomial
trend line, order 2) for MSFsc as a function of age, sepa-
rately for females (n = 665; R2 = 83%) and males (n =
1030; R2 = 90%) with this norm data (see the solid lines
in Fig. 1). During evaluation of these best fit lines of the
norm data, we noticed an unnatural increase in MSFsc at
older ages, which has not been noted in the literature [14].
There was therefore a risk that we might find the
hypothesised earlier sleep-wake behaviour in RA merely
because of these unnaturally high values in the norm group
at older ages. To minimise this risk, we fixed the
MSFsc,norm values for older ages at a lower (earlier) val-
ue: at 4:00 h from the age of 67 years for females, and at
3:52 h from the age of 72 years for males (see Fig. 1 a and
b) . This resul ted in the fol lowing formulas for
MSFsc,norm:
Females
Subjects age≤67 y : MSFsc; norm in hoursð Þ ¼ 0:0015
 age2– 0:1631 ageþ 8:0348
Subjects age > 67 y : MSFsc; norm in hoursð Þ ¼ 4:00
Males
Subjects age≤72 y : MSFsc; norm in hoursð Þ ¼ 0:0009
 age2– 0:1244 ageþ 8:1618
Subjects age > 72 y : MSFsc; norm in hoursð Þ ¼ 3:87
¼ 3:52 h : mmð Þ
Data from medical records (study aim 2)
Disease activity data were extracted from medical records of
the most recent EAC measurement preceding the completion
of the questionnaires (on average 5.3 months [median
5.6 months] ± SD 2.8 months [range: between 7 days and
10 months]). Disease activity was assessed using the Disease
Activity Score (DAS) based on a 44-joint score for swollen
joint count, and a Ritchie Articular Index (53 joints) for joint
pain on palpation.
From the same EACmeasurement, the duration of morning
stiffness was assessed as an ordinal variable with seven cate-
gories: no morning stiffness, 1–30 min, 30–60 min, 1–2 h, 2–
4 h, > 4 h, whole day. The presence of morning stiffness was
examined in the current study as a categorical variable (yes/
no) in two ways: (1) no morning stiffness vs. the other cate-
gories; (2) < 1 h vs. > 1 h.
Calculations and statistics
Data were analysed with SPSS Statistics for Windows
(Version 23, IBM Corporation, Armonk, NY, USA).
Study aim 1
For each subject in our RA sample, we calculated the differ-
ence between (1) the MSFsc based on the MCTQ filled in by
the subject, and (2) the MSFsc,norm based on the age and
gender of the subject, using the formulas presented above.
This difference, ΔMSFsc, expresses the number of minutes
by which the MSFsc of a certain RA subject deviates from the
MSFsc of the norm group. A ΔMSFsc of zero means no
difference; a positive value indicates a later chronotype; and
a negative value indicates an earlier chronotype for the subject
with RA in comparison with the norm group.
Main analysis A one-sample t test was conducted to examine
whether ΔMSFsc deviated significantly from 0. A p value <
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0.05was considered significant. Cohen’s dwas calculated as a
measure of effect size.
Additional exploratory analyses As the norm data were dom-
inated by subjects of a younger age, we performed two addi-
tional exploratory analyses including only the youngest part of
our sample: (1) one analysis excluded females > 67 years and
males > 72 years (i.e. the ages at which the norm values were
fixed); and (2) one analysis excluded subjects whose age lays
above the mean age of the RA sample (i.e. 60 years).
Study aim 2
Main analyses To relate chronotype to disease outcomes, we
created four equally sampled groups based on MSFsc (from
early to late chronotype): ‘≤ 3:00 h’ (n = 29); ‘3:00–3:30 h’
(n = 30); ‘3:31–4:00 h’ (n = 34); and ‘>4:00 h’ (n = 28).
MSFsc was categorised for this analysis to keep open the
possibility of a non-linear relationship.
To compare the chronotype groups on disease outcome
measures, we performed one-way ANOVA analyses (CIS-
scores), Kruskal-Wallis analyses (HR-QoL subscale scores
and DAS scores), and chi-square analyses (presence of MS).
As these analyses were explorative, an uncorrected p value of
< 0.05 was considered significant.
Additional exploratory analyses For additional exploratory
purposes, the relations between the continuous measure of
chronotype (i.e. MSFsc) and the outcomes were also
explored.
In addition, we explored the relation between ΔMSFsc and
outcomes. ΔMSFsc was considered both a continuous and a
categorical variable (compared to the norm: ≥ 1 h earlier (n =
25); 1 h to 15 min earlier (n = 44); 15 min earlier to 15 min







































Fig. 1 Plot of the MSFsc values
in females (a) and males (b).
Open circles represent the average
values of the norm group subjects
(the average valueswere available
per 2 years from 18 to 60 years,
and from 60 to 65 years and 65 to
80 years). Error bars show the
standard deviations. The solid
lines represent the MSFsc,norm
values used (see text for
formulas). The closed circles
represent the MSFsc of each
individual subject with RA; the
squares are outliers. The dotted
lines show the average MSF in
our RA sample for females (i.e.
3:28 h:mm) and males (i.e.
3:32 h:mm). ΔMSFsc was
determined by subtracting
MSFsc,norm from MSFsc and
expressing the number of minutes
by which the MSFsc of a certain
subject deviates from the MSFsc
of the average subject with the





Of the patients invited by a postal letter (n = 178), 34% par-
ticipated (27% on paper, 7% online). Of the patients invited by
email (n = 127), 54% participated (53% online, 1% on paper
[after request]). This resulted in 129 subjects (response rate:
42%; paper: n = 49, online: n = 80). Eight subjects were ex-
cluded because the MSFsc could not be determined due to
incomplete MCTQ (n = 3), or because they had engaged in
shift work in the 3 months before the measurement (n = 5).
The mean age of the remaining 121 subjects was 60 years
(SD: 12, range: 23–85 years), with 88 females and 33 males.
The participants had a median disease duration of 6 years
(IQR: 10), and the median Disease Activity Score (DAS44)
was 1.6 (IQR: 1.2). Fifty-three percent of the sample worked;
the median weekly number of work days of those subjects was
four (IQR: 2). Sixteen percent of the subjects used an alarm
clock on free days. The median time spent outdoors was 2.0 h/
day (IQR: 1.8). Corticosteroids were used by eight partici-
pants. For more patient characteristics, see Online Resource 1.
Study aim 1
Descriptives The MSFsc and ΔMSFsc of five subjects were
marked as unusually extreme outliers (3 extremely late and 2
extremely early); these subjects were therefore excluded for
the one-sample t test and the subsequent descriptives. The
MSFsc and ΔMSFsc were normally distributed with an
MSFsc mean ± SD of 3:29 h:mm ± 41 min. See Fig. 1 for
the subjects’ individual MSFsc values. Table 1 gives an over-
view of the main sleep variables as obtained with the MCTQ.
Background analysesMSFsc was strongly related toΔMSFsc
(rs = .916, n = 116, p < 0.001). An earlier MSFsc was related
to an earlier time point of sleep onset on free days (rs
(114) = .686, p < 0.001), an earlier time point of sleep end on
free days (rs (114) = .755, p < 0.001), and a shorter sleep du-
ration on free days (rs (114) = .227, p = 0.014). Online
Resource 2 shows all correlations between the main sleep
variables.
The sleep variables presented in Table 1 are not related to
age, gender, or disease duration (p > 0.05), except for the sleep
end (averaged over the week), which was positively related to
age (rs (114) = .203, p = 0.029).
Main analysis A one-sample t test showed that the ΔMSFsc
deviated significantly from 0 (t(115) = − 5.901, p < 0.001, d =
0.55); the MSFsc was on average 23 min (95% CI, 15 to
31 min) earlier in RA patients than in the norm group.
Additional exploratory analyses The two analyses including
only the youngest part of our sample (see “Materials and
methods”) confirmed the findings of the main analysis, show-
ing an earlier MSFsc in the RA patients than in the norm
group: on average (1) 21 (95% CI, 12 to 30), and (2) 26
(95% CI, 14 to 38) min (p < 0.001).
Another exploratory analysis showed that, without exclu-
sion of the five subjects with extreme early or late
chronotypes, also an average significant deviation was found
(of 21 min [95% CI, 11 to 31, p < 0.001]).
Study aim 2
Main analysis Table 2 shows the descriptives and statistics of
disease activity, reported morning stiffness, fatigue, and HR-
QoL for each chronotype group. None of these measures dif-
fered to a statistically significant extent between the four
chronotype groups (p > 0.05; see Table 1).
Additional exploratory analyses No relationship was found
between the continuous measure of chronotype and the out-
comes (p > 0.05).
The analyses exploring the relation between ΔMSFsc and
outcomes showed an indication for a relationship between the
number of swollen joints and ΔMSFsc (categorical ΔMSFsc:
X2(3) = 12.451; p = 0.006; continuous ΔMSFsc: rs = .224, p =
0.016). The relation was unexpectedly in favour of subjects
with a much earlier chronotype as compared to subjects with
MSFsc values close to those in the norm group (see Online
Resource 3).
Study aim 3
According to the Holland Sleep Disorder Questionnaire, 37%
of the subjects presented one or more sleep disorders; a circa-
dian rhythm sleep disorder was present in 4% of the subjects
(see also Online Resource 4).




Sleep onset Free days 23:37; 50
Week average 23:30; 48
Sleep end Free days 7:36; 68
Week average 7:16; 58
Sleep duration Free days 7:59; 76
Week average 7:46; 71
MSFsc 3:29; 41




A previous study showed an earlier timing of the circadian
rhythm, reflected by earlier peaks in serum melatonin levels
during the night [4]. In line with this, in the current study, we
found (as expected) an earlier chronotype in patients with RA
than in subjects from the general population.
An earlier chronotype, reflected in the current study by
mid-sleep, could result from earlier sleep onset and/or earlier
sleep end. Although deviations in sleep onset and sleep end
were not explored in the current study, patients’ accounts sug-
gested that they both fall asleep and awaken earlier than
desired.
Although there are indications that patients with RA have
both an earlier chronotype (this study) and an earlier internal
circadian pacemaker (indicated by earlier peaks of melatonin
during the night [4]), it is unclear how those two rhythms are
related within an individual patient. It would be interesting to
examine the time between melatonin onset and bedtime/sleep
onset time (i.e. phase angle) to find out whether patients with
RA go to bed and/or start sleeping at the optimal time after
their melatonin levels start rising [15]. A possible misalign-
ment might be related to patient-reported outcomes (e.g. fa-
tigue) and disease activity.
In the main analyses, no relations were found between
chronotype and disease activity, reported morning stiffness,
fatigue, or HR-QoL. One additional explorative analysis gave
us an indication for a possible relation: subjects with a much
earlier chronotype than the norm group had unexpectedly on
average less number of swollen joints than those with a
chronotype close to the subjects in the norm group. As this
was an additional explorative analysis and uncorrected p values
were used, this finding should be confirmed in another study.
Possible explanations for the absence of relations between
chronotype and disease activity include (1) the subjective na-
ture of some of the measurements used (e.g. fatigue, HR-QoL,
and sleep times), which reduces the comparability between
subjects; (2) the fact that measurements of chronotype and
disease activity were not performed on the same day (on av-
erage there were 5 months between these measurements,
Table 2 Descriptives of disease activity, morning stiffness, fatigue, and health-related quality of life and test statistics of the comparison of the four
chronotype groups (n = 121)
All Group
Outcome measure <3.0 h 3.0–3.5 h 3.5–4.0 h >4.0 h Test statistic p
Median (IQR) Mean rank χ2(3)
Disease activity (DAS44) 1.62 (1.17) 60 61 63 59 0.264 0.967
Visual analogue scale (0–100 mm) pain, mm 20 (50) 68 64 52 62 3.737 0.291
Visual analogue scale (0–100 mm) general well-being, mm 30 (30) 66 58 59 62 0.987 0.804
Erythrocyte sedimentation rate, mm/h 9 (16) 58 65 59 62 0.917 0.821
Ritchie tender joint index 1 (3) 60 58 67 58 1.663 0.645
Number of swollen joints 0 (1) 53 56 70 65 5.729 0.126
Reported morning stiffnessa n present (%) n present (%) χ2(3)
Morning stiffness presenceb 65 (60%) 16 (59%) 18 (67%) 15 (48%) 16 (67%) 2.678 0.444
Morning stiffness >1 h 12 (11%) 3 (11%) 3 (11%) 3 (10%) 3 (12%) 0.111 0.990
Fatigue (Checklist Individual Strength) Mean ± SD Mean ± SD F(3,117)
Checklist Individual Strength-20 72±26 75±21 69±22 77±28 68±31 0.958 0.415
Checklist Individual Strength-8 34±12 36±12 31±11 35±13 32±14 1.116 0.326
Health-related quality of life (RAND-36)c Median (IQR) Mean rank χ2(3)
Subscale general health perception 50 (30) 56 64 53 68 3.543 0.315
Subscale health change 50 (25) 66 57 56 64 1.997 0.573
Subscale role functioning; physical problems 50 (100) 61 59 56 64 1.009 0.799
Subscale role functioning; emotional problems 100 (50) 61 64 58 61 0.669 0.880
Subscale energy/fatigue 55 (30) 61 66 55 61 1.586 0.663
Subscale pain 67 (35) 59 53 60 62 0.273 0.965
Subscale physical functioning 75 (34) 59 61 64 59 0.442 0.931
Subscale social functioning 75 (25) 52 65 56 69 4.459 0.216
Subscale mental health 80 (24) 58 62 53 71 4.689 0.196
a 12 subjects missing; b 1–30 min, 30–60 min, 1–2 h, 2–4 h, > 4 h, whole day vs. no morning stiffness; c 0–2 subjects missing
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which complicates the interpretation of a correlation analysis);
(3) the presence of several fatigue subtypes; (4) the presence
of pain; (5) the low average disease activity in our sample,
which reduces the variability in this measure; and/or (6) the
possible influence of pharmacological medication (e.g. corti-
costeroids) on both disease activity and circadian rhythmicity
(note: corticosteroids were used by very few patients in our
sample).
Alternatively, it is possible that the outcomes are related
not to chronotype but to the timing of the internal circadian
pacemaker. Although chronotype is influenced by the internal
circadian pacemaker, several other factors are also involved:
social factors (e.g. work and social activities); environmental
factors (e.g. time point and amount of light exposure and
physical activity); and the rate of the accumulation (falling
asleep) and dissipation (awaking) of the homeostatic sleep
pressure.
Therefore, for future studies, it might be fruitful to examine
whether measurements of the circadian rhythm (i.e. endoge-
nous measures such as the timing of the internal circadian
pacemaker as measured with dim light melatonin onset) are
related to disease activity and patient-reported outcomes.
Furthermore, it would be interesting to investigate the earlier
timing of the internal circadian pacemaker and chronotype in
relation to more specific patient-reported measures (rather
than the general measure of fatigue applied in the current
study) such as the feeling of sleepiness in the early evening
and sleeplessness in the early morning which could influence
HR-QoL.
Given that a correlational study does not establish causali-
ty, we are unable to draw conclusions about whether an earlier
chronotype has an effect on disease activity and patient-related
outcomes. It would be of interest to examine whether experi-
mentally delaying the circadian rhythm in patients with an
earlier rhythm—thus establishing a later rhythm that is possi-
bly more aligned with the external light-dark cycle—would
make the patients feel less fatigued (possibly due to better
sleep quality and/or a reduction of inflammatory activity dur-
ing the night). One way to induce a delay of this kindwould be
through light exposure in the evening [16]. Rao et al. [17]
elaborate extensively on the promising role of circadian re-
alignment in improving RA outcomes.
In our sample, the proportion of sleep disorders among the
RA participants was comparable to that of a general Dutch
population [12]. Our finding of an earlier chronotype could
indicate the presence of an advanced sleep-wake phase as
defined by the ICSD. However, the questionnaire used for
measuring circadian rhythm sleep disorders does not explicit-
ly measure the advanced sleep-wake phase disorder. This
could explain the fact that a circadian rhythm sleep disorder
was found in only a small number of the participants, which
was comparable to the general Dutch population [12].
Furthermore, patients with RA may not have a circadian
rhythm sleep disorder, but only an advanced chronotype
(without this being a disorder).
The subjects in the RA sample had a mean age of
60 years; however, the norm group included only fifty
individuals above this age. Therefore, the norm values
used in the age group above 60 years may be less reliable.
This uncertainty is increased by the fact that our best fit
lines show an unnatural increase in chronotype (i.e. later)
at older ages, whereas earlier studies show that people’s
chronotype increases from approximately 20 years [14].
To avoid the risk of finding the hypothesised earlier
chronotype in RA just because of the unnaturally high
values at older ages in the norm group, we fixed the values
of the norm group at older ages at a lower (earlier) value,
and still found an earlier chronotype. This finding was
confirmed by exploratory analyses including only subjects
of a lower age. Nevertheless, it is recommended for future
studies to use a norm group with more persons in the age of
interest (e.g. partners of patients).
Only 42% of the patients invited to participate decided to
do so; this may have led to selection bias. As patients were
informed in advance what the study was about, it is possible
that patients with sleep concerns were more willing to partic-
ipate. This could have affected the generalisability of the
results.
In summary, we found an earlier chronotype in RA; this is
in line with a previous finding that the timing of the internal
circadian pacemaker is earlier in RA patients than in people
from the general population. In this correlational study, an
earlier chronotype does not seem to be related to several de-
bilitating symptoms observed in RA, such as fatigue. An ex-
perimental study is needed to examine whether delaying the
circadian rhythm has a positive influence on fatigue and other
outcomes. Furthermore, future studies should examine wheth-
er those symptoms are related to measurements of circadian
timing (e.g. dim light melatonin onset). This insight can im-
prove our understanding of the pathophysiology of RA and
contribute to the exploration of new treatment possibilities.
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